NASDAQ:INSY INSYS Therapeutics (INSY) Stock Price, News & Analysis → Biden replacement revealed? (From Paradigm Press) (Ad) Free INSY Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.23▼$65,799,000.0052-Week Range N/AVolumeN/AAverage Volume9.52 million shsMarket Capitalization$21.71 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get INSYS Therapeutics alerts: Email Address Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. About INSYS Therapeutics Stock (NASDAQ:INSY)Insys Therapeutics, Inc., a specialty pharmaceutical company, focuses on cannabinoids and drug delivery systems that address unmet patient needs. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It also develops Cannabidiol Oral Solution, a synthetic cannabidiol, for the treatment of rare childhood epilepsy syndromes that include west syndrome and childhood absence epilepsy, as well as glioblastoma multiforme, pontine glioma, and pediatric schizophrenia. In addition, the company develops Buprenorphine Sublingual Spray for acute pain; Epinephrine Nasal Spray for allergic reactions, including anaphylaxis; and Naloxone Nasal Spray for opioid antagonist. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.Read More Ad WealthPress$25,000 into $109,616 in two months? Today I want to show you how our research shows you could’ve grown a $25,000 account into $109,616.12 within the last TWO months. You see, former multi-million dollar hedge fund manager Roger Scott spent the better half of 2023 developing what might be the most advanced trading tool that exists… It’s a revolutionary software system that tracks the moves of institutional investors…. in real time…Go here to watch the most recent trading workshop video at no charge. INSY Stock News HeadlinesMarch 29, 2024 | forbes.comHow Sam Bankman-Fried’s 25 Year Sentence Stacks Up Against Other Billionaire, Ex-Billionaire ConvictsMarch 15, 2024 | msn.comPort Clinton man sentenced for illegal dispensing narcoticsApril 25, 2024 | Insider Financial (Ad)Thousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.March 12, 2024 | finance.yahoo.comSofinnova Investments Appoints Troy Ignelzi as Executive AdvisorMarch 3, 2024 | msn.comMeet John Kapoor: The CEO and Founder of Insys Who Played a Role in the Fentanyl CrisisMarch 1, 2024 | yahoo.comLehighton doctor settles with U.S. for alleged False-Claim Act violationsDecember 18, 2023 | forbes.comHow Trevor Milton’s 4 Year Prison Sentence Stacks Up Against Other Billionaire And Ex-Billionaire Convicts.December 5, 2023 | msn.comTampa doctor must pay $1.5 million for part in ‘Pain Hustlers’ schemeApril 25, 2024 | Insider Financial (Ad)Thousands of investors use this no cost solution | Do you? In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.November 2, 2023 | msn.comNetflix Pain Hustlers: Ex-Boca school counselor used exotic dancer, models to push fentanylNovember 2, 2023 | msn.comThe Real Inspiration Behind Pain Hustlers' Liza Drake ExplainedNovember 1, 2023 | msn.comPain Hustlers on Netflix: Meet the master Boca Raton salesman behind the real Insys storyOctober 31, 2023 | msn.comEx-Boca school counselor used exotic dancer, models to push fentanylOctober 31, 2023 | msn.comNetflix Pain Hustlers: Former exotic dancer from West Palm Beach sentenced in fentanyl scamOctober 31, 2023 | msn.com‘Pain Hustlers’: The True Story Behind Chris Evans and Emily Blunt’s New Netflix MovieOctober 30, 2023 | msn.comIs Liza Drake From Pain Hustlers A Real Person? Director Explains Emily Blunt's CharacterOctober 30, 2023 | msn.comA Fictitious Drug Takes Center Stage in 'Pain Hustlers' but Is the Story Itself Also Fake?October 30, 2023 | msn.comFlorida doctor accepted $160K in bribes to prescribe unnecessary fentanyl, feds sayOctober 30, 2023 | finance.yahoo.comRapport Therapeutics Appoints Chief Financial OfficerOctober 30, 2023 | msn.comThe Ending of ‘Pain Hustlers,’ ExplainedOctober 30, 2023 | news.yahoo.comSpray form of fentanyl is one of most dangerous prescribed drugsOctober 30, 2023 | msn.comWhat Happened To The Real Dr. Jack Neel After Pain HustlersOctober 30, 2023 | msn.comThe True Story That Inspired 'Pain Hustlers,' ExplainedOctober 28, 2023 | msn.comPain Hustlers Ending Explained: Why did Liza, Pete, and Jack end up in prison?October 28, 2023 | msn.comChris Evans’ Cringey ‘Pain Hustlers’ Rap Is Inspired By a Real Rap Video Made By Ex-Pharma ExecutivesOctober 27, 2023 | msn.comIs 'Pain Hustlers' Based On A True Story? All About Insys Therapeutics And John KapoorOctober 27, 2023 | msn.comIs Lonafen A Real Drug In Netflix's Pain Hustlers?See More Headlines Receive INSY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for INSYS Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/10/2019Today4/25/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:INSY Previous SymbolNASDAQ:NEOL CUSIPN/A CIK1516479 Webwww.insysrx.com Phone480-500-3127FaxN/AEmployees226Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.39) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-124,510,000.00 Net Margins-346.61% Pretax MarginN/A Return on Equity-1,430.37% Return on Assets-64.04% Debt Debt-to-Equity RatioN/A Current Ratio0.54 Quick Ratio0.50 Sales & Book Value Annual Sales$82.08 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.58) per share Price / BookN/AMiscellaneous Outstanding Shares74,570,000Free FloatN/AMarket Cap$21.71 million OptionableOptionable Beta3.21 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Steven J. Meyer (Age 62)Exec. Chairman Mr. Saeed Motahari (Age 53)CEO, Pres & Director Mr. Andrew G. LongChief Financial OfficerDr. Danny L. TuckSr. VP of Quality OperationsMr. Franc Del Fosse (Age 47)Sr. VP of Corp. Affairs Key CompetitorsTherapeuticsMDNASDAQ:TXMDLisata TherapeuticsNASDAQ:LSTAIndaptus TherapeuticsNASDAQ:INDPMEI PharmaNASDAQ:MEIPSynlogicNASDAQ:SYBXView All Competitors INSY Stock Analysis - Frequently Asked Questions How were INSYS Therapeutics' earnings last quarter? INSYS Therapeutics, Inc. (NASDAQ:INSY) posted its quarterly earnings results on Friday, May, 10th. The specialty pharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by $0.33. The specialty pharmaceutical company had revenue of $7.63 million for the quarter, compared to analyst estimates of $14.95 million. INSYS Therapeutics had a negative trailing twelve-month return on equity of 1,430.37% and a negative net margin of 346.61%. The business's revenue was down 68.1% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.19) EPS. When did INSYS Therapeutics' stock split? Shares of INSYS Therapeutics split on the morning of Monday, March 31st 2014. The 3-2 split was announced on Tuesday, March 4th 2014. The newly created shares were issued to shareholders after the closing bell on Friday, March 28th 2014. An investor that had 100 shares of stock prior to the split would have 150 shares after the split. What other stocks do shareholders of INSYS Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other INSYS Therapeutics investors own include Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), Zynerba Pharmaceuticals (ZYNE), Puma Biotechnology (PBYI), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Micron Technology (MU), (MDVN) (MDVN) and NVIDIA (NVDA). This page (NASDAQ:INSY) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyThe #1 Crypto for 2024InvestorPlaceEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsFed launches fourth dollar overhaulStansberry ResearchUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American Alternative1970’s computer coder issues shocking A.I. warningTradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INSYS Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
